Bicalutamide , ≥98%(HPLC),powder , 90357-06-5

Synonym(s):
Bicalutamide (CDX);Casodex;Cosudex;N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide

CAS NO.：90357-06-5

Empirical Formula: C18H14F4N2O4S

Molecular Weight: 430.37

MDL number: MFCD00869971

EINECS: 200-001-8

PRODUCT Properties

• Melting point: 191-193°C
• Boiling point: 650.3±55.0 °C(Predicted)
• Density: 1.52±0.1 g/cm3(Predicted)
• storage temp.: 2-8°C
• solubility: DMSO: >5mg/mL
• form: powder
• pka: 11.49±0.29(Predicted)
• color: White to Off-White
• λmax: 270nm(CH3CN)(lit.)
• Merck: 14,1200

Description and Uses

Bicalutamide was launched in the United Kingdom, its first worldwide market, for the treatment of advanced prostate cancer in combination with an LHRH analog or surgical castration. A non-steroidal, peripherally selective antiandrogen, bicalutamide inhibits the action of dihydrotestosterone and testosterone at target sites by competitive binding to the cytosolic androgen receptor. It was reportedly well tolerated with no significant cardiovascular and metabolic side effects due to the benefit of lacking any steroid activity. The efficacy of bicalutamide as a monotherapy has been demonstrated clinically. Promising response rates were also reported in treating colorectal, breast, pancreas and non-small cell lung cancers.

These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Safety

• Symbol(GHS): GHS08,GHS09
• Signal word: Danger
• Hazard statements: H351-H360FD-H410
• Precautionary statements: P202-P273-P280-P308+P313-P391-P405
• Hazard Codes: Xi
• Risk Statements: 36/37/38
• Safety Statements: 26-36-24/25
• RIDADR: 3077
• WGK Germany: 3
• RTECS: TX1413500
• HazardClass: 9
• PackingGroup: III
• HS Code: 29242995